Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
November 01, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
October 10, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
August 10, 2023 07:00 ET
|
Monopar Therapeutics Inc.
Camsirubicin Phase 1b Trial Currently at 5th Dose-Level (650 mg/m2), Generating Encouraging ResultsMNPR-101 Radiopharma Program Advancing Toward First-in-Human Studies WILMETTE, Ill., Aug. 10, 2023...
Monopar Provides Encouraging Camsirubicin Clinical Data Update
August 08, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for...
Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
July 11, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today...
Monopar to Participate in the Radiopharma Forum by the Lake 2023
June 21, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., June 21, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
June 14, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update
June 01, 2023 07:00 ET
|
Monopar Therapeutics Inc.
Patient in 520 mg/m2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients in the 520 mg/m2 cohort achieved stable...
Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
May 11, 2023 07:00 ET
|
Monopar Therapeutics Inc.
Camsirubicin Phase 1b DoseEscalation Trial Enrolling 5th DoseLevel Cohort (650 mg/m2)MNPR-101 RIT Shows Promising Imaging and Therapeutic Preclinical Study ResultsWILMETTE, Ill., May 11, 2023 (GLOBE...